Butaprost

Butaprost is a selective prostaglandin E receptor (EP2) agonist with an EC50 of 33 nM and a Ki of 2.4 μM for murine EP2 receptor. Butaprost is less activity against murine EP1, EP3 and EP4 receptors. Butaprost attenuates fibrosis by hampering TGF-β/Smad2 signalling[1][2][3].

Product Specifications

CAS Number

[69685-22-9]

UNSPSC

12352211

Hazard Statement

H225, H319, H336

Target

Prostaglandin Receptor; TGF-beta/Smad

Type

Reference compound

Related Pathways

GPCR/G Protein; Stem Cell/Wnt; TGF-beta/Smad

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/butaprost.html

Concentration

12.24 mM * 200 μL in Methyl acetate

Purity

99.2

Solubility

10 mM in DMSO

Smiles

COC(CCCCCC[C@@H](C(C[C@H]1O)=O)[C@H]1/C=C/C[C@@H](C2(CCC2)CCC)O)=O

Molecular Formula

C24H40O5

Molecular Weight

408.57

Precautions

H225, H319, H336

References & Citations

[1]Yanbin Liang, et al. Upregulation of orphan nuclear receptor Nur77 following PGF (2alpha), Bimatoprost, and Butaprost treatments. Essential role of a protein kinase C pathway involved in EP (2) receptor activated Nur77 gene transcription. Br J Pharmacol. 2004 Jun;142 (4) :737-48.|[2]Michael Schou Jensen, et al. Activation of the prostaglandin E 2 EP 2 receptor attenuates renal fibrosis in unilateral ureteral obstructed mice and human kidney slices. Acta Physiol (Oxf) . 2019 Sep;227 (1) :e13291.|[3]K Tani, et al. Design and synthesis of a highly selective EP2-receptor agonist. Bioorg Med Chem Lett. 2001 Aug 6;11 (15) :2025-8.